IL-2联合GP方案对非小细胞肺癌近期疗效及免疫功能变化的研究

Study of curative effect in the near future and immune function changes of non-small cell lung cancer (NSCLC) with the program of IL-2 combined with GP

目的探讨IL-2联合GP方案对非小细胞肺癌(NSCLC)患者近期疗效及免疫功能变化的影响。方法选择40例患者使用GP/3+IL-2方案治疗,并与40例使用GP/4方案治疗的患者比较近期疗效、不良反应以及对免疫功能的影响。结果两组疾病控制率差异无统计学意义(P>0.05);治疗组发生恶心呕吐和血小板减少的比例显著低于对照组(P<0.05);治疗后治疗组CD3和CD4的百分比均显著高于对照组(P<0.05),同时治疗组CD4/CD8水平显著高于对照组(P<0.05)。结论 IL-2联合GP方案治疗NSCLC患者临床疗效满意,不良反应少,且对患者的免疫功能影响小,是一种有效和安全的治疗方法。

Objective To investigate the influence of curative effect in the near future and immune function changes of non-small cell lung cancer （NSCLC） with the program of IL-2 combined with GP.Methods Forty patients used GP/3 and IL-2 regimen were chosen,and they were given the comparison of another 40 cases used GP/4 regimen with short-term efficacy,adverse reactions and immune function.Results The two groups with disease control rate had no differences （P 0.05）,treatment group with proportion of nausea,vomiting and thrombocytopenia occurred were lower than that of the control group （P 0.05）.The percent of CD3 and CD4 were higher than that of control group （P 0.05）,CD4/CD8 levels were higher than that of control group （P 0.05）.Conclusion The treatment of IL-2 combined with GP for NSCLC has satisfactory clinical curative effect,with less adverse reactions,and the impact on the immune function of patients is small,which is an efficacy and safety treatment method for NSCLC.